

July 21, 2022

Notice of Termination of the Recombinant Human Serum Albumin Business

Mitsubishi Tanabe Pharma Corporation (Head Office: Chuo-ku, Osaka; Representative Director: Hiroaki Ueno; hereinafter, "MTPC"), a member of the Mitsubishi Chemical Group, announced that it has decided to terminate its recombinant human serum albumin business.

MTPC has been discussing with a contract manufacturer about resuming sales of Medway® Injection 25%, a recombinant human serum albumin preparation. However, as a manufacturing method that can withstand quality maintenance and a stable supply cannot be established, MTPC has decided not to resume supply. In association with this, the business related to manufacturing of recombinant human serum albumin is terminated.

<p>Mitsubishi Chemical Group Corporate Communications Division Osaka Corporate Communications Department Media contacts: [+81] (0)6-6205-5119</p>
